Angina Pectoris Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Angina Pectoris Drugs Market Analysis

The Angina Pectoris Drugs Market is expected to register a CAGR of 6.6% during the forecast period, 2022-2027.

COVID-19 severely impacted the angina pectoris market during the early pandemic due to the lockdown restrictions, a decrease in the number of patient hospital visits, and supply chain disruption. For instance, the article titled "COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?" published in Pain Medicine, in November 2020, stated that the number of cardiovascular patients attending emergency rooms has decreased in the case of COVID-19. Patients have attributed the contradiction to a COVID-19 phobia, meaning that people with angina pectoris avoid going to emergency rooms since they were afraid of becoming infected with the virus. Such incidents negatively impacted the market's growth in the initial phase of the outbreak. However, the demand for angina pectoris drugs is likely to increase with the growing implications of heart disease among COVID-19 patients. For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit. Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for drugs. Therefore, the growing number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.

Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the augmentation of novel drug delivery systems.

One of the major driving factors for the market growth is the surge in the patient population suffering from cardiac disorders such as coronary heart disease. For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2019. Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55. Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Thus, the growing number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the analysis period, thereby driving the market growth. However, increasing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may hinder the market's growth in the coming years.

Angina Pectoris Drugs Market Trends

This section covers the major market trends shaping the Angina Pectoris Drugs Market according to our research experts:

Beta Blockers is Expected to Exhibit a Significant CAGR Over the Forecast Period

To understand key trends, Download Sample Report

Angina Pectoris Drugs Industry Segmentation

As per the scope of the report, Angina pectoris refers to a strangling or pressure-like pain caused by cardiac ischemia. Angina drugs are the initial treatment of angina pectoris. The antianginal drugs recommended for initial treatment are β blockers and calcium channel blockers, which reduce myocardial ischemia by heart rate reduction and vasodilatory mechanisms, respectively. Either or both of these drug classes should be prescribed, together with a short-acting nitrate for prompt alleviation of angina attacks. The Angina Pectoris Drugs Market is segmented by therapeutic class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors, Anti-Platelets, and Others) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for all the above segments.

Report scope can be customized per your requirements. Click here.